Four top-line data readouts expected in 2022 from ongoing oral AMT-101 Phase 2 trials, as follows FILLMORE monotherapy trial for patients with chronic pouchitis followed by MARKET combination trial with anti-TNF α in ulcerative colitis (UC) in H1 2022 LOMBARD monotherapy trial in UC and CASTRO

SOUTH SAN FRANCISCO, Calif., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc. (Nasdaq: AMTI) (AMT), a clinical-stage biopharmaceutical company, today announced that Tahir Mahmood, Ph.D., chief executive officer and co-founder, will participate in a fireside chat during the SVB

John W. Smither Appointed to its Board of Directors and Named Audit Committee Chair Graham K. Cooper Named Executive Chair Helen S. Kim Named Lead Independent Director SOUTH SAN FRANCISCO, Calif., Jan. 27, 2022 (GLOBE NEWSWIRE) -- Applied Molecular Transport Inc.